UK markets closed

TSHA Jul 2024 1.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.4500-0.9500 (-67.86%)
As of 11:22AM EDT. Market open.
Full screen
Previous close1.4000
Open0.4500
Bid0.2000
Ask1.2000
Strike1.50
Expiry date2024-07-19
Day's range0.4500 - 0.4500
Contract rangeN/A
Volume1
Open interest21
  • GlobeNewswire

    Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

    DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972

  • GlobeNewswire

    Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its comm

  • GlobeNewswire

    Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome

    Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid ta